Company News

Avicanna Inc. ("Avicanna" or the "Company") (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, is pleased to announce the appointment of Eileen McCormack to, and the resignation of Setu Purohit from, its board of directors effective immediately.

Eileen McCormack is an experienced senior marketing executive with more than 30 years of international experience in the bio-pharmaceutical industry. Ms. McCormack retired from AstraZeneca US where she led commercial and cross-functional teams responsible for launch planning and business development in the US market. Ms. McCormack has experience in bio-pharmaceutical product development, portfolio strategy in complex regulated environments and brings significant multi-market and international commercial experience. Ms. McCormack gives back to her community by having served on a number of national and Toronto-based non-for-profit boards over the last 10 years.

"I am excited to be joining the Avicanna board of directors," said Eileen McCormack. "I believe Avicanna has a strong business model and talented management team that uniquely positions it to capitalize on the evolving cannabinoid-based biopharmaceutical industry. I look forward to contributing to Avicanna's future growth and success as the company executes development and launch activities for its evidence-based products."

"We are pleased to add Ms. McCormack to our board of directors at an appropriate time where her experience and wisdom can support the next phase of evolution of the Company, including pipeline analysis and global commercialization efforts," stated Aras Azadian, CEO Avicanna Inc.

About Avicanna

Avicanna is a Canadian commercial-stage biopharmaceutical company established in cannabinoid research, development, and evidence-based products for the global consumer, as well as medical and pharmaceutical market segments. In leading global cannabinoid advancements, Avicanna conducts most of its research in Canada at its R&D headquarters in the Johnson & Johnson Innovation Centre, JLABS @ Toronto, located in the MaRS Discovery District. The company actively collaborates with leading Canadian academic and medical institutions. Avicanna has established an industry-leading scientific platform including advanced R&D and clinical development which has led to the commercialization of over twenty products across four main market segments:

  • Medical Cannabis & Wellness Products: Marketed under the RHO Phyto™ brand, or Magisterial Preparations, these medical and wellness products are an advanced line of pharmaceutical-grade cannabis products containing varying ratios of cannabidiol ("CBD") and tetrahydrocannabinol ("THC"). The product portfolio contains a full formulary of products including oral, sublingual, topical, and transdermal deliveries that have controlled dosing, enhanced absorption and stability studies supported by pre-clinical data. The advanced formulary is marketed with consumer, patient and medical community education and training. Avicanna's medical and wellness product portfolio also forms the foundation of the Company's pharmaceutical pipeline with the contribution of the formulations that form the basis of the products as well as the data generated from sales and participation of the products in real world evidence studies.
  • CBD Derma-Cosmetic Products: Marketed under the Pura H&W™ or Pura Earth™ brands, these registered, clinically tested, derma-cosmetic products include a portfolio of functional CBD topical products.
  • Pharmaceutical Pipeline: Leveraging Avicanna's scientific platform, vertical integration, and real-world evidence, Avicanna has created a pipeline of patent-pending drug candidates which are indication-specific and in various stages of clinical development and commercialization. These cannabinoid-based drug candidates provide solutions for unmet medical needs in the areas of dermatology, chronic pain, and various neurological disorders. Avicanna's first pharmaceutical preparation (Trunerox) is in the drug registration stage in South America.
  • Cannabis Raw Materials, Seeds, and Bulk Formulations: Marketed under the Aureus™ brand, the Company's raw material business has successfully completed sales to 11 countries. Aureus offers cannabis dried flower, standardized seeds, full spectrum extracts, and cannabinoid distillates, isolated cannabinoids (CBD, THC, cannabigerol ("CBG") and other rare cannabinoids), and bulk formulations derived from hemp and cannabis cultivars through its sustainable, economical, and industrial-scale subsidiaries based in Colombia. The majority of the Aureus products are produced at Santa Marta Golden Hemp S.A.S. ("SMGH"), the Company's majority-owned subsidiary, which is also Good Agricultural and Collection Practices ("GACP") certified and has United States Department of Agriculture ("USDA") National Organic Program certification for its hemp cultivar.

SOURCE Avicanna Inc.

Stay Connected

For more information about Avicanna, visit www.avicanna.com , contact Ivana Maric by email at info@avicanna.com or follow us on social media on LinkedIn , Twitter , Facebook or Instagram .

The Company posts updates through videos from the official company YouTube channel https://www.youtube.com/channel/UCFXPBGdKSxOUOf_VZoSFSUA .

Cautionary Note Regarding Forward-Looking Information and Statements

This news release contains "forward-looking information" within the meaning of applicable securities laws. Forward-looking information contained in this press release may be identified by the use of words such as, "may", "would", "could", "will", "likely", "expect", "anticipate", "believe, "intend", "plan", "forecast", "project", "estimate", "outlook" and other similar expressions . Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management in light of management's experience and perception of trends, current conditions and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment, the availability of licenses, approvals and permits, and the utility and potential application of certain drugs, cannabinoids, compounds and products. Although the Company believes that the expectations and assumptions on which such forward looking information is based are reasonable, undue reliance should not be placed on the forward looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to current and future market conditions, including the market price of the common shares of the Company, and the risk factors set out in the Company's annual information form dated September 3, 2021 and final short form prospectus dated November 27, 2020, filed with the Canadian securities regulators and available under the Company's profile on SEDAR at www.sedar.com. The statements in this press release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

AVCN:CA
Avicanna Reports Q1 2022 Financial Statement and Management Change

Avicanna Reports Q1 2022 Financial Statement and Management Change

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS

Avicanna Inc. (" Avicanna " or the " Company ") (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the commercialization of evidence-based, cannabinoid-based products, is pleased to announce the filing of its interim financial statements for the three-month period ending March 31, 2022 (" Q1 2022 ") and the transition of the role of Chief Financial Officer.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Mycotopia Therapies Inc. Update on Ei.Ventures and Strategic Investments

Mycotopia Therapies Inc. Update on Ei.Ventures and Strategic Investments

Mycotopia Therapies Inc. (OTC Pink: TPIA), a biopharma company focused on research, technology, and the development of medical psychedelics, and Ei.Ventures Inc., a technology company empowering mental wellness through psychoactive compounds, nutraceuticals and web 3.0, are pleased to announce several strategic investments to advance the combined company's business plan. Ei.Ventures completed its Regulation A+ financing round on March 22, 2022 after announcing plans to go public in a $360 million transaction with Mycotopia Therapies on December 07, 2021.

The combined company will be renamed PSLY.COM and focus its efforts on developing fungi and plant based Botanical Psychedelic API and Therapeutics instead of single molecule synthetic drugs with the belief that research will continue to confirm the importance of a synergistic approach. This will set PSLY.COM apart from virtually every other company in the space developing synthetic versions of Psilocybin. Ei.Ventures holds the IP for the extraction process of three botanical potential API compounds, Psilocybin, DMT and MDMA. PSLY.COM plans to further develop this API and file a Drug Master File with the FDA, which will provide the opportunity to potentially sell the API to other organizations while protecting its IP.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Avicanna Announces Closing of Strategic Private Placement

Avicanna Announces Closing of Strategic Private Placement

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS

Avicanna Inc. (" Avicanna " or the " Company ") (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the commercialization of evidence-based, cannabinoid-based products, is pleased to announce that it has closed a strategic non-brokered private placement offering of 4,210,931 ‎‎units of the Company (the " Units ") at a price of $0.35 per Unit for aggregate gross proceeds of approximately $1.475 million (the " Offering "). Each Unit is comprised of one common share in the capital of the Company (each, a " Common Share ") and one-half of one (0.5) Common Share purchase warrant of the Company (each whole warrant, a " Warrant "). Each Warrant shall entitle the holder thereof to acquire one (1) Common Share at an exercise price of $0.40 per share, subject to adjustment in certain events, for a period of 36 months.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Avicanna Expands RHO PhytoTM Formulary with the Introduction of Cannabigerol  Products into the Canadian Market

Avicanna Expands RHO PhytoTM Formulary with the Introduction of Cannabigerol Products into the Canadian Market

Avicanna introduces the rare cannabinoid CBG into its RHO Phyto product formulary which includes oral, sublingual, and transdermal formulations

RHO Phyto CBG products will be made available through various medical and adult-use channels across Canada by Q3 2022

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Avicanna Enters into Exclusive License and Supply Agreement with Major South American Pharmaceutical Company

Avicanna Enters into Exclusive License and Supply Agreement with Major South American Pharmaceutical Company

Avicanna Inc. ("Avicanna" or the "Company") (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development and commercialization of plant-derived medical and pharmaceutical cannabinoid-based products, is pleased to announce that it has entered into an exclusive license and supply agreement with an established South American pharmaceutical company to commercialize up to four (4) of Avicanna's proprietary cannabinoid-based pharmaceutical preparations.

The intellectual property related to Avicanna's proprietary cannabinoid-based pharmaceutical preparations was originally developed through the company's well established drug delivery platform and further studied through various Canadian research collaborations where the formulations demonstrated stability and bioavailability. The pharmaceutical form of these formulations was then manufactured in Colombia, through the Company's global vertical integration, where the cannabinoid raw material is also sourced from the Company's cultivation and extraction infrastructure.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Curaleaf Appoints Tyneeha Rivers As Chief People Officer

Curaleaf Holdings, Inc. (CSE: CURA OTCQX: CURLF) ("Curaleaf'' or the "Company"), a leading international provider of consumer products in cannabis, announced today that Tyneeha Rivers has been appointed to the role of Chief People Officer for Curaleaf, a new position.

The move follows the recent announcement of Matt Darin being named CEO, replacing Joe Bayern , who will be launching a new CPG focused division of the Company.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
AgriForce to Present at the H.C. Wainwright Global Investment Conference on May 25th

AgriForce to Present at the H.C. Wainwright Global Investment Conference on May 25th

AGRIFORCE Growing Systems Ltd. ("the Company") (NASDAQ: AGRI; AGRIW) an intellectual property (IP)-focused AgTech company dedicated to advancing sustainable cultivation and crop processing across multiple verticals, today announced that Ingo Mueller, Chief Executive Officer of AGRIForce, will be presenting at the H.C. Wainwright Global Investment Conference which is being held on May 23- May 26, 2022 at the Fontainebleau Miami Beach Hotel, Miami FL. The conference will include virtual and in-person participation.

Mr. Mueller is scheduled to present in-person on Wednesday, May 25, 2022 at 12:00 p.m. ET. Management will also be available for one-on-one meetings with qualified investors throughout the conference.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
person working on laptop

Cannabis Weekly Round-Up: Cresco and Columbia Care Share Q1 Financials

A pair of US cannabis companies that are tied together by an acquisition plan released their quarterly financials this week. Cannabis delivery services were in focus as well as two companies confirmed their plans to offer seamless delivery solutions for cannabis consumers.

Keep reading to find out more cannabis highlights from the past five days.

Keep reading...Show less

Canopy Growth Kicks Off Summer Long Weekends with Exciting New Product Line-Up

Canadian cannabis market leader introduces new offerings across its house of brands 7ACRES, Ace Valley, Deep Space and Doja

SMITHS FALLS, ON , May 20, 2022 /CNW/ - Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX: WEED) (NASDAQ: CGC), a world-leading diversified cannabis, hemp, and cannabis device company, today unveiled a line-up of new offerings across its premium brand portfolio – 7ACRES, Ace Valley, Deep Space and Doja. With select products releasing just in time for the first long weekend of the summer, including the release of its first large format premium flower offering for the recreational market, Doja 91K 14g, this new line-up builds on the Company's continued commitment to product innovation and meeting evolving consumer demand, while cementing Canopy's leadership position in the premium flower market.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
pair of hands holding cannabis buds

Lift Expo Show Floor Marked by Calls for Cannabis Action and Unity

The most recent edition of the Lift & Co. Expo, held this past weekend in Toronto, brought multiple calls to action among cannabis industry stakeholders.

In panels at the show and in conversations with the Investing News Network (INN), experts used this year’s event to urge all types of cannabis companies to collaborate in high-level lobbying.

During the event, a distinct theme appeared: the need for firms in the cannabis market to better advocate for themselves in front of the Canadian government.

Keep reading...Show less

Trulieve Celebrates Two Medical Dispensary Openings in West Virginia

South Charleston and Parkersburg locations both opening on Saturday, May 21 at 10 a.m.

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the United States today announced the grand opening of its third and fourth medical dispensaries in West Virginia . Located at 4701 MacCorkle Ave. SW in South Charleston and 152 Park Shopping Center in Parkersburg both dispensaries will open at 10 a.m. on Saturday, May 21, 2022 .

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×